Biora licenses wound healing project to Molnlycke
This article was originally published in Clinica
Executive Summary
Swedish company Biora has formed a licensing agreement with Molnlycke Health Care for a wound healing product, intended for use in the treatment of chronic skin ulcers. Molnlycke gets exclusive rights to develop and market the product worldwide, excluding Japan. Biora will get up to SKr45 million ($4.3 million), including SKr10 million upfront, from the arrangement.